雷米普利治疗高血压病对NO、vWF的影响  

The influence of ramipril on plasma nitric oxide and von-Willebrand factor in the treatment of essential hypertension

作　　者：张玮[1] 姚璐[2] 王强[1] 郑东诞[1] 

机构地区：[1]中山大学附属第一医院黄埔院区心内科,广东广州510700 [2]中山大学附属第一医院黄埔院区神经内科,广东广州510700

出　　处：《海南医学院学报》2005年第6期510-511,共2页Journal of Hainan Medical University

摘　　要：目的:评价雷米普利治疗轻、中度高血压病对一氧化氮(NO)、内皮血管性血友病因子(vWF)的影响。方法:选取轻、中度高血压病患者36例及正常对照组32例,高血压病组服用雷米普利5mg/d,治疗前、治疗3个月后及正常对照组行血浆NO、vWF检测。结果:治疗前血浆NO较正常对照组降低(P<0.05),治疗后血浆NO较治疗前明显升高(P<0.01)。治疗前血浆vWF较正常对照组明显升高(P<0.01),治疗后血浆vWF较治疗前降低(P<0.05)。结论:雷米普利明显升高血浆NO、降低vWF,说明它在降压的同时具有保护血管内皮细胞的功能。Objective： To evaluate the effects of Ramipril on plasma nitric oxide and vonWillebrand factor （vWF） in treating the patients with grade 1 or grade 2 the essential hypertension. Methods： 36 cases of patients with grade 1 or grade 2 the essentia hypertension and 32 normal persons were selected. The hypertention group was treated with Ramipril 5 mg/d. Both Plasma NO and vWF were tested before and after 3 months treatment. Results： The plasma NO before treatment in the essentia hypertension group decreased significantly than normal group （P〈0.05） and plasma NO after treatment raised significantly than that before treatment （P〈0.01）. The plasma vWF before treatment in the essentia hypertension group raised significantly than normal group （P〈0.01）and plasma vWF after treatment decreased than that before treatment（P〈0.05）. Conclusion： Ramipril raises plasma NO and decreases plasma vWF significantly. It is shown that Ramipril not only reduces hypertension but also protects function of vascular endothelial cells.

关 键 词：高血压 一氧化氮 内皮 血管 Von Willebran因子 雷米普利 

分 类 号：R544.1[医药卫生—心血管疾病]